Response Genetics Q4 Revenues Down 13 Percent on Lower Pharma Client Business | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostic testing firm Response Genetics today reported a 13 percent drop year over year in its fourth quarter revenues.

For the three months ended Dec. 31, 2013, the Los Angeles-based company recorded revenues of $4.8 million, down from $5.5 million in Q4 2012. While Response DX test revenues were up 3 percent year over year, pharmaceutical client revenues were down 35 percent year over year, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.